Roche/Abbvie's Venclexta Outshines Agios IDH Inhibition In AML At ASH
Clinicians weigh in on updated data presented at ASH in frontline acute myeloid leukemia, but caution that it is difficult to compare across clinical trials.
You may also be interested in...
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Enrolment In the Phase III TAHOE study has been halted due to shorter overall survival in the Rova-T arm compared with the control arm.
The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.